Recent Posts
Yes, I like this idea!
I think there is a brilliant opportunity right before our eyes for this forum to do an internal research project involving mineral's db or a further development of it. So many pros.
Do you think some non-professional like us can publish our own scientific study leaning on mineral's database ?
Some sites like medrxiv accept to publish preprint studies. I tell myself that if we were doing serious work we have a chance to be accepted...
It remains to be seen whether this decision was a chance one, but the first positive results have been noticeable for 2 to 3 weeks now. What had happened: out of sheer fear of dying and despair, I had started taking donepezil 5mg in mid-April, which I had been given immediately after the diagnosis at the beginning of February, without really believing that it could help me. As the months went by and I felt no improvement, I continued to look for solutions to POIS because it had been with me virtually all my life, I came across xolair in the POIS forum in the USA. To keep it short in the first step, I was unfortunately refused the prescription this week, I have to go to a pneumologist in the hospital environment because the drug is very special, expensive and therefore not covered by health insurance. An appointment will follow on 10 October in Saverne, further information on this part will follow in October at the earliest, as the 75 mg injections are administered 6 to 8 weeks apart.
In the meantime, since the end of August, I can report an almost unbelievable development in my condition. My life now makes sense again, I am able to talk, think, memorise and pronounce several words or sentences.
Now, what is it? My guess, which I will find out from the professeur in Strasbourg on 15 October, is the donepezil 5mg. I have been taking it for almost 5 months now, my condition has improved so much that I can no longer remember such a cognitive performance, thinking and speaking ability. I can now speak fluently again, write long, extensive texts again, and the great thing is that my courage to face life is almost completely back.
Some antidepressant/anti-anhedonic medications and Alzheimer's medications like donepezil also happen to act as Sigma-1 receptor agonists, and this action likely contributes to their therapeutic effects on cognition. In summary, Sigma-1 receptors play an important neuromodulatory role in various processes fundamental to learning and memory. Sigma-1 agonists continue to show promise as cognitive enhancers, especially under pathological conditions involving cholinergic or glutamatergic deficits.
Donepezil mediates oligodendrocyte differentiation by activating both ERa and ERB. Western blotting revealed that the donepezil-mediated increased expression of MAG and MBP was inhibited following treatment with antagonists of ERa and ERB. These findings demonstrated that ERa and ERB play important roles in donepezil-induced oligodendrocyte differentiation as indicated by the expression of myelin-associated protein.
https://onlinelibrary.wiley.com/doi/full/10.1111/jnc.14927
…[POIS] hasn't got sufficient attention from the researchers…
Thankfully, this is changing!Please check out/search the forum:• 2025 upcoming *major* NORD POIS Research Study - UCLA & University of Nebraska• Universities of Chicago & Massachusetts (UMass)• Tulane University
Adding this one of
• Charité University Clinic in Berlin: https://poiscenter.com/forums/index.php?topic=4524
…[POIS] hasn't got sufficient attention from the researchers…
Thankfully, this is changing!
Please check out/search the forum:
• 2025 upcoming *major* NORD POIS Research Study - UCLA & University of Nebraska
• Universities of Chicago & Massachusetts (UMass)
• Tulane University
I guess I might be the first African to post about POIS.
